Communiqués Valeritas Holdings, Inc.

Actions

VLRXQ

US91914N3017

Equipement, fournitures et distribution médicale

Temps Différé OTC Markets Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-4,76%	-96,52%

06/07/20	Zealand Pharma : va ouvrir des bureaux à Boston
20/12/19	Valeritas Holdings, Inc. met à jour ses prévisions de chiffre d'affaires pour le quatrième trimestre et l'année 2019, ainsi que pour le premier trimestre 2020.	CI

Communiqués

02/04/20	VALERITAS HOLDINGS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23/03/20	Valeritas : Receives Court Approval of Sale of Business to Zealand Pharma	PU
20/03/20	VALERITAS HOLDINGS INC. : Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/03/20	Valeritas : Receives Court Approval of Sale of Business to Zealand Pharma	PR
18/03/20	VALERITAS HOLDINGS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
16/03/20	VALERITAS HOLDINGS INC. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events (form 8-K)	AQ
28/02/20	VALERITAS HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)	AQ
15/02/20	VALERITAS HOLDINGS INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
10/02/20	VALERITAS HOLDINGS INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/01/20	VALERITAS HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23/12/19	VALERITAS HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)	AQ
20/12/19	VALERITAS HOLDINGS INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/12/19	Valeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full Year	GL
11/12/19	VALERITAS HOLDINGS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
09/12/19	VALERITAS HOLDINGS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
09/12/19	Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting	GL
20/11/19	VALERITAS HOLDINGS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
15/11/19	Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage	GL
12/11/19	Valeritas Announces Third Quarter 2019 Financial Results	GL
29/10/19	Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)	GL
21/10/19	Valeritas : GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study	PU
21/10/19	GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study	GL
15/10/19	Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia	GL
10/10/19	Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting	GL
08/10/19	Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2019)	GL